ZEITSCHRIFT FUR GASTROENTEROLOGIE胃肠病学杂志
ZEITSCHRIFT FUR GASTROENTEROLOGIE(英文缩写 Z GASTROENTEROL),ISSN 0044-2771,eISSN 1439-7803,中文译名:胃肠病学杂志 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-11-01 至 2026-10-31，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 1.769 | Q4 |
| 2022 | 1.300 | Q4 |
| 2023 | 1.400 | Q4 |
| 2024 | 1.600 | Q3 |
| 2025 | 1.700 | Q4 |
ZEITSCHRIFT FUR GASTROENTEROLOGIE 最新收录文献
-
3. [New Therapeutic Approaches for MASH: Mechanisms and Clinical Promise].
3. [MASH的新型治疗策略：机制与临床前景]PMID:日期:2026-09-23Metabolic dysfunction-associated steatotic liver disease (MASLD) is a progressive liver disorder characterized by inflammation, fibrosis, and metabolic dysfunction. In recent years, therapeutic options have expanded significantly. The thyroid hormone receptor-β agonist resmetirom became the first drug approved in Germany in 2025 for non-cirrhotic MASH with moderate to advanced fibrosis. Furthermore, incretin mimetics, originally developed for diabetes and obesity, are being investigated. In a phase 3 study, semaglutide demonstrated significant improvements in hepatic inflammation and fibrosis. Beyond GLP-1 analogs, which act indirectly through metabolic pathways, several liver fibrosis-specific therapies are emerging, including FGF-21 analogs and dual incretin receptor agonists (e.g. survodutide) that directly affect hepatocytes via glucagon receptor signaling. Combination therapies are increasingly being explored to harness synergistic effects and enable individualized treatment. Ongoing phase 3 studies assess long-term efficacy and safety. In parallel, biomarkers are being refined for patient selection and treatment monitoring. The German SLD Registry will collect patient data and clinical outcomes following the implementation of new therapies. This review summarizes recent advances and future perspectives in the pharmacological treatment of MASH. The combination of metabolic and liver-targeted therapies offers substantial promise for personalized medicine.
-
4. Metabolic and Bariatric Surgery as a Therapeutic Option for MASLD: Outcome, Mechanism, and Long-Term Implications.
4. 代谢与减重手术作为MASLD的治疗选择：结局、机制及长期影响PMID:日期:2026-09-23Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease and a major hepatic manifestation of metabolic syndrome. It is closely linked to obesity and type 2 diabetes mellitus. While many patients display a steatotic liver, some progress to steatohepatitis, fibrosis, and cirrhosis, increasing the risk of hepatocellular carcinoma (HCC). Current management targets metabolic risk factors. Metabolic and bariatric surgery (MBS) has therefore emerged as both an obesity treatment and a therapeutic option for MASLD. This narrative review summarizes evidence on clinical outcomes, efficacy, and mechanisms. Histology-based studies show MASLD resolution and relevant fibrosis regression after MBS, with durable benefits. Comparative studies indicate superiority over lifestyle intervention and conservative treatment, while direct comparisons with modern drugs (e.g. GLP-1 agonists) remain limited. Mechanistic studies suggest that MASLD remission by MBS is driven through a combination of sustained weight loss and surgery-specific effects on hepatic lipid metabolism, mitochondrial function, glucose metabolism, incretin and bile acid signalling, adipose tissue biology, and the gut-liver axis. Emerging evidence suggests fewer liver-related events and lower HCC incidence, with potential benefits in selected high-risk patients. In conclusion, MBS is not merely a weight loss intervention, but a disease-modifying, multi-system metabolic therapy with direct hepatic effects.
-
5. MetALD: Terminology, Implications, and Therapeutic Considerations.
PMID:日期:2026-09-23With the introduction of steatotic liver disease (SLD) as an umbrella term and metabolic dysfunction-associated steatotic liver disease (MASLD) as one of its major subcategories, a new diagnostic category was proposed to better reflect the coexistence of metabolic dysfunction and alcohol consumption: MetALD. MetALD identifies individuals with hepatic steatosis and cardiometabolic risk factors whose alcohol intake exceeds MASLD thresholds but remains below the levels typical of alcohol-related liver disease. The prevalence of MetALD in the general population is approximately 4%. Evidence suggests that MetALD is associated with more severe liver-related outcomes and higher all-cause mortality compared to MASLD, although findings are not entirely consistent. Despite these risks, MetALD remains underdiagnosed because alcohol consumption is often self-reported and underestimated due to recall bias, social desirability bias, or stigma. Consequently, managing MetALD requires a multidisciplinary approach addressing both cardiometabolic comorbidities and alcohol-related behavioral factors. MetALD should be viewed not only as a medical condition but also as a disorder with significant behavioral and social dimensions that influence diagnosis, treatment adherence, and long-term outcomes. This review discusses the clinical implications and therapeutic considerations specific to this newly introduced terminology.
-
6. MASLD: Established Knowledge and Emerging Directions - Guideline Updates.
6. MASLD：既有认知与新兴方向——指南更新PMID:日期:2026-09-23Metabolic dysfunction-associated steatotic liver disease (MASLD) has become a major global health challenge, largely driven by the increasing prevalence of obesity and type 2 diabetes mellitus. The disease spectrum ranges from isolated steatosis to metabolic dysfunction-associated steatohepatitis (MASH) with progressive fibrosis. Advanced fibrosis substantially increases the risk of cirrhosis, hepatocellular carcinoma, and cardiovascular complications, thereby contributing significantly to morbidity and mortality.Although lifestyle modification remains the cornerstone of therapy, pharmacological treatment is gaining importance in patients with progressive disease or high-risk profiles. Advances in the understanding of MASLD pathophysiology have enabled the development of targeted therapies addressing hepatic lipid accumulation, insulin resistance, inflammation, and fibrogenesis. Promising clinical data have been reported for resmetirom, semaglutide, tirzepatide, survodutide, lanifibranor, and fibroblast growth factor-21 analogues including efruxifermin, pegozafermin, and efimosfermin.This review summarises current and emerging diagnostic and therapeutic strategies and provides practical guidance for clinical management. In addition, a structured treatment algorithm for non-cirrhotic MASLD (F0-F3), restricted to therapies currently available in Europe and stratified according to diabetes status and fibrosis stage, is proposed as an evidence-based tool for routine clinical practice.
-
8. Adherence to Mediterranean diet in outpatients with inflammatory bowel diseases is low, and only weakly associated with clinical outcomes - a single-center observational study.
PMID:日期:2026-09-17Dietary behavior is associated with the course of several somatic and mental disorders. In inflammatory bowel diseases (IBD), where mental health is frequently impaired, adherence to recommended Mediterranean diet (MD) and its clinical relevance remain unclear. This study investigated MD adherence in IBD outpatients and its associations with disease activity and psychosocial outcomes. 430 patients completed questionnaires assessing adherence to MD (MEDAS), depression and anxiety (HADS), fatigue (FACIT-F), and quality of life (SHS). Network analysis using Spearman correlations was performed to visualize associations among parameters. Adherence to MD was low (median MEDAS = 6), with the greatest deficits in fish (11.2%), fruits (15.3%), and pulses (18.1%). Adherence was higher in female than in male patients (6 vs 5, p=0.002). Depressive symptoms were present in 24.3%, anxiety in 40.6%, and severe fatigue in 33.6% of patients. Fatigue, depression and anxiety formed a dense cluster in the network analysis and strongly linked to quality of life, while MD was only weakly related to other parameters. Our data show low MD adherence and high levels of fatigue, symptoms of anxiety and depression that are strongly linked to quality of life and disease activity.
-
9. Therapeutic Management of Wilson Disease in Clinical Practice: Multicenter Retrospective Real-World Data from Germany.
PMID:日期:2026-09-17Wilson disease (WD) is a rare disorder of copper metabolism. Chelating agents available include D-penicillamine (DPA) and trientine (TETA-2HCl and TETA-4HCl). Real-world data on treatment sequencing and formulation switches are limited. This study aimed to retrospectively analyze real-world treatment patterns in WD patients receiving trientine therapy in Germany. We retrospectively collected data from patients treated with trientine at six specialized centers between 01/2012 and 12/2021. Inclusion criteria were documented initiation of trientine and at least one follow-up visit. We analyzed treatment duration, number of treatment lines, and dosing during switches. Reasons for switching therapy and clinical outcome data were not systematically collected. A total of 143 patients were included. Monitoring across centers involved non-ceruloplasmin-bound copper, 24-hour urinary copper excretion, and transient elastography. Data on prior DPA therapy were available for 109 patients (mean duration: 11 years). Fifty percent were switched to trientine within 7 years of DPA therapy, while the remaining switches occurred after up to 48 years. Patients received a mean of 3.3 lines of therapy (range: 1-6). Mean switch factors were 0.75 for DPA to TETA-2HCl and 0.6 for DPA to TETA-4HCl. For switching between TETA-2HCl and TETA-4HCl, factors were 0.84 and 1.27, respectively. These real-world data describe WD treatment management at specialized German centers. The observed dose changes during formulation switches are descriptive and hypothesis-generating, but prospective studies with clinical outcome data are needed before any switch factor can be recommended for routine practice.
-
10. Cholangiocarcinoma in a 33-year-old male with CD40L deficiency and pre-papillary bile duct stenosis.
PMID:日期:2026-08-20X-linked hyper IgM-syndrome caused by CD40L deficiency is a rare primary immunodeficiency. Affected male individuals who reach adulthood often develop sclerosing cholangitis. Here, we report the case of a 33-year-old patient with long-standing solitary pre-papillary bile duct stenosis but without further signs of sclerosing cholangitis, who developed distal cholangiocarcinoma. Given the increased risk of malignancy in these patients, this case highlights, that individuals with CD40L deficiency should be screened for the presence of cholangiopathy and be closely monitored for any signs of disease progression, development of hepatobiliary dysplasia or malignancy.